Platinum-based anticancer drugs, including cisplatin, carboplatin, oxaliplatin, nedaplatin,
and lobaplatin, are heavily applied in chemotherapy regimens. However, the intrinsic or …

Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis, with a median survival
time of 10-12 months. Clinically, these poor outcomes are attributed to several factors …

Platinum-based chemotherapy, including cisplatin, carboplatin, and oxaliplatin, is prescribed
to 10-20% of all cancer patients. Unfortunately, platinum resistance develops in a significant …

Cisplatin is one of the most effective broad-spectrum anticancer drugs. Its effectiveness
seems to be due to the unique properties of cisplatin, which enters cells via multiple …

Oxaliplatin was the first platinum drug with proven activity against colorectal tumors,
becoming a standard in the management of this malignancy. It is also considered for the …

Oxaliplatin was the third Pt-based anticancer drug to be clinically used worldwide. It exhibits
a broad spectrum of anticancer activity and was the first to be approved for the treatment of …

Cisplatin and other platinum (II) analogs are widely used in clinical practice as anti-cancer
drugs for a wide range of tumors. The primary mechanism by which they exert their action is …

Background Nutrient deprivation, hypoxia, radiotherapy and chemotherapy induce
endoplasmic reticulum (ER) stress, which activates the so-called unfolded protein response …

Over 80% of ovarian cancer patients develop chemoresistance which results in a lethal
course of the disease. A well-established cause of chemoresistance involves the family of …

Oxaliplatin-based chemotherapy is widely used to treat advanced hepatocellular carcinoma
(HCC), but many patients develop drug resistance that leads to tumor recurrence. Cancer …